Unaudited Consolidated Balance Sheets - USD ($) $ in Millions	Sep. 30, 2017		Dec. 31, 2016
Current Assets
Cash and cash equivalents (variable interest entity restricted - 2017: $23; 2016: $18)	$ 461		$ 638
Trade receivables - third party and affiliates (net of allowance for doubtful accounts - 2017: $8; 2016: $6; variable interest entity restricted - 2017: $5; 2016: $4)	989		801
Non-trade receivables, net	260		223
Inventories	809		720
Marketable securities, at fair value	31		30
Other assets	63		60
Total current assets	2,613		2,472
Investments in affiliates	938		852
Property, plant and equipment (net of accumulated depreciation - 2017: $2,508; 2016: $2,239; variable interest entity restricted - 2017: $706; 2016: $734)	3,706		3,577
Deferred income taxes	201		159
Other assets (variable interest entity restricted - 2017: $6; 2016: $9)	306		307
Goodwill	995	[1]	796
Intangible assets (variable interest entity restricted - 2017: $25; 2016: $26)	303		194
Total assets	9,062		8,357
Current Liabilities
Short-term borrowings and current installments of long-term debt - third party and affiliates	435		118
Trade payables - third party and affiliates	695		625
Other liabilities	343		322
Income taxes payable	77		12
Total current liabilities	1,550		1,077
Long-term debt, net of unamortized deferred financing costs	2,954		2,890
Deferred income taxes	195		130
Uncertain tax positions	153		131
Benefit obligations	845		893
Other liabilities	230		215
Commitments and Contingencies
Stockholders' Equity
Preferred stock, $0.01 par value, 100,000,000 shares authorized (2017 and 2016: 0 issued and outstanding)	0		0
Treasury stock, at cost (2017: 32,387,713 shares; 2016: 26,950,910 shares)	(2,031)		(1,531)
Additional paid-in capital	171		157
Retained earnings	4,781		4,320
Accumulated other comprehensive income (loss), net	(206)		(358)
Total Celanese Corporation stockholders' equity	2,715		2,588
Noncontrolling interests	420		433
Total equity	3,135		3,021
Total liabilities and equity	9,062		8,357
Series A common stock, $0.0001 par value, 400,000,000 shares authorized (2017: 168,024,095 issued and 135,636,382 outstanding; 2016: 167,611,357 issued and 140,660,447 outstanding)
Stockholders' Equity
Common stock	0		0
Series B common stock, $0.0001 par value, 100,000,000 shares authorized (2017 and 2016: 0 issued and outstanding)
Stockholders' Equity
Common stock	$ 0		$ 0

[1] There were $0 million of accumulated impairment losses as of September 30, 2017.